Streetbeat News

ICCM

IceCure Medical Ltd

https://www.icecure-medical.com

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

1.38

Mkt cap

80M

Volume

166K

High

1.44

P/E Ratio

-5.07

52-wk high

1.66

Low

1.38

Div yield

N/A

52-wk low

0.48

IceCure Medical Ltd. (NASDAQ:ICCM) announced that the FDA Advisory Panel will meet on November 7, 2024, to discuss the marketing authorization of ProSense, a cryoablation technology for early-stage low-risk breast cancer. A decision is expected by early 2025.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:09 pm

IceCure Medical Ltd. (NASDAQ:ICCM) has received a Notice of Allowance from the USPTO for a continuation patent on its 'Cryogenic Pump' technology, enhancing its global IP leadership in cryoablation technologies. This patent broadens the applications of IceCure's platform, with over 50 patents issued worldwide.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:32 pm

HC Wainwright & Co. has maintained a Buy rating on Icecure Medical but lowered the price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:53 am

IceCure Medical shares rose following the release of their Q2 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 4:49 pm

Icecure Medical reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.06), beating the estimate of $(0.07), and sales of $1.01M, surpassing the $925.50K estimate. This marks a 7.90% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 12:39 pm

IceCure Medical reported a half-year EPS of $(0.14), an improvement from $(0.17) last year.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 12:36 pm

IceCure Medical announced that a study concluded cryoablation is a safe and effective alternative to surgery for early-stage breast cancer patients. The treatment was well-tolerated and accepted by most non-surgical patients.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:34 pm

IceCure Medical Ltd. (NASDAQ: ICCM) announced the publication of an independent study in the British Journal of Radiology, which found that cryoablation is a safe and effective alternative to surgery for early-stage breast cancer. The study showed a 100% complete ablation rate for Luminal A and B breast cancer tumors ≤ 25mm after a median follow-up of 16 months.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:33 pm

IceCure Medical announced the publication of an independent study in the American Journal of Roentgenology, showing high recurrence-free rates in higher-risk breast cancer patients using cryoablation. The study reported rates of 94.7%, 87.8%, and 81.8% at 1, 2, and 3 years, respectively.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:36 pm

IceCure Medical presented key findings on its ProSense breast cancer treatment at the Japanese Breast Cancer Society meeting, showing high success rates and low recurrence. Terumo Corporation plans to seek regulatory clearance in Japan by Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.